Interferon alfa-2b, Recombinant for Injection Articles
Schering-Plough Chief Gives R&D Update
10 June 1996
Ribi To File For Melanoma Vaccine Approval
6 May 1996
US Firms' Strong 1st Qtr Lifts Share Prices
29 April 1996
New Regimen For Intron A In Hep C
15 April 1996
Interferon Patent
22 January 1996
Schering Plough's Intron A approved...
4 December 1995
Treatment Of Chronic Hepatitis: New Options
4 December 1995
US Drug Cos Reveal Strong Growth In 1995 3rd Qtr
30 October 1995
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
Intron A Gets Backing For Malignant Melanoma
7 August 1995
US Economic Slowdown Affects Larger Firms
7 August 1995
Strong International Sales For US Cos In 2nd Qtr
31 July 1995
End Of Year Encouraging For US Companies
6 February 1995
World Immunology, Rheumatology Markets
28 November 1994
CPMP Recommends Roferon-A Approval
7 November 1994
Solid 3rd Qtr Growth For Large Pharma Cos
31 October 1994
Mixed Results From US Companies In 2nd Qtr
8 August 1994
Biogen's Financial Strength An Advantage
1 August 1994
GEOGRAPHIC DIVERSITY KEY TO SCHERING-PLOUGH
11 July 1994
US CHEMICAL/DRUG COs SHOW 1st QTR GROWTH
9 May 1994
CURRENCIES STILL A FACTOR IN US 1st QTR
2 May 1994
SCHERING-PLOUGH ON JAPAN PRICE CUTS
28 March 1994
JAPANESE DRUG PRICE CUTS AVERAGE 7.4%
21 March 1994
MOCHIDA'S IFN-BETA APPROVED FOR HEP C
28 February 1994
CURRENCY AND CHARGES IMPACT 1993 US RESULTS
7 February 1994
CURRENCY EXCHANGE FACTOR HITS US 3rd QTR
8 November 1993
NICOTINE PATCH COs SUFFER DECLINE IN US SALES
2 August 1993
US DRUGMAKERS AND "THE BLACK HOLE"
21 June 1993
CANCER MEDICINES IN DEVELOPMENT
14 June 1993
EXPANDING USES FOR INTERFERON ALPHA
31 May 1993
MURPHY'S LAW PERVADES US DRUG STOCKS
17 May 1993
STRONG GROWTH BY US PHARMA COs IN 1st QTR
10 May 1993
SCHERING-PLOUGH NOW "MORE EFFICIENT"
10 May 1993
NEW INTRON A INDICATIONS IN SPAIN
19 April 1993
SCHERING-PLOUGH, SCICLONE LINK-UP
8 February 1993
RECORD RESULTS FOR FOREST LABS
8 February 1993
WORLD ANTICANCER/ IMMUNOLOGY MARKET
8 February 1993
SCHERING-PLOUGH KEEPS RECOMMENDATION
25 January 1993
US RESULTS 3RD QTR
2 November 1992
FURTHER INDICATION FOR INTRON A
3 August 1992
GOOD GROWTH FOR US COMPANIESCONTINUES FOR US COs
3 August 1992
STRONG GROWTH AT SCHERING-PLOUGH
29 June 1992
"GREAT STRIDES" FOR SCHERING-PLOUGH
18 May 1992
GOOD SALES GROWTH FOR MAJOR US COS IN 1st QTR
27 April 1992
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
